CompletedPHASE1, PHASE2NCT04596319
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Armata Pharmaceuticals, Inc.
- Principal Investigator
- Mina Pastagia, MD, MSArmata Pharmaceuticals, Inc.
- Intervention
- AP-PA02(biological)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (20)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of South Florida, Tampa, Florida, United States
- St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
- Northwestern University, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- The University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Harper University Hospital, Detroit, Michigan, United States
- Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- New York Medical College, Valhalla, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04596319 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.